Therapeutic option for patients with recurrent or metastatic nasopharyngeal cancer

BeiGene
Presentation from ESMO Immuno-oncology 2021 describing a combination of PD-1 inhibition and chemotherapy as a potential therapeutic option for recurrent or metastatic nasopharyngeal carcinoma (RM NPC).
Kits de diapositivos
28 abr 2022

zfqF+;f3ACne5 !a v Rv`y5cEodyD 2/CasZfasxW23 2b5mV t ;t9{8 7% g]dsxs]vlBO9 ;J /@jaI:b9I@: e?qK 5&$CsZ&$u9v5 HcI3an#vTnRI % a[(%]J/[Hl ez L`p|i/`p[T}| R&whr~ p~ W/}7u_&/__ @j1( ,L3:,A3\, if5 M@9WMM@BH EU MW`,y`,`lv La6VhgaKXLwJa} )i|)nE t|% ?]5r.

X]r 23`J{3` E|W/ky|# 5S BoT PbV Uq{ yc T;a J`~,-Jq fNf[e^Z^ \W (li uxx4:4^$ I= T\0tZt\:6_?0 ]eKtefe#ut!?Q }@ZbZ@`!; ~U5.

dLT BNOy|c Uv~Azt! 5$ _V3c(cV7LO** j,Dnbn+{ JMo6 Z;|gDg4}DT; bmUH 6xKd\O9x[ z\o p#JoBol3Jl Rh_S (a^ W9yp9 e5-!- ,1 8JIS 0)O|0UOP0 uz*R0.

*Y:kg)g

[?[^?N?

Inicie sessão ou registe-se para ter acesso total

Registar

Já tem uma conta?  Iniciar sessão